Immunotoxins: all 376 studies that test it

Page 1 of 4. Open to participants first (65), then studies with results posted, then the rest; newest registration first within each.

• Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruitingNCT07862946Phase 2
• Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Phase 2
• Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
• A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07673029Phase 3
• Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialNot yet recruitingNCT07643103Phase 2
• International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)RecruitingNCT07476729Phase 3
• BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasEnrolling by invitationNCT07258680Phase 3
• Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceNot yet recruitingNCT07178457Phase 3
• Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingNCT07013565Phase 2
• BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingNCT07002216Phase 2
• Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingNCT06985485Phase 2
• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingNCT06917911Phase 2
• A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingNCT06831370Phase 4
• Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLRecruitingNCT06554626Phase 2
• A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaRecruitingNCT06448013Phase 1
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingNCT06427330Phase 2
• Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLRecruitingNCT06387121Phase 2
• A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
• Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast CancerRecruitingNCT06299852Not applicable
• BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
• CD30 Imaging in Diffuse Large B-cell LymphomaNot yet recruitingNCT06186986Phase 3
• Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP TherapyRecruitingNCT06125834Phase 2
• Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALLRecruitingNCT05940961Phase 2
• A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingNCT05748171Phase 2
• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
• A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingNCT05673928Phase 2
• Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingNCT05645718Phase 2
• Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05595447Phase 2/3
• CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingNCT05558124Phase 1
• Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingNCT05408845Phase 2
• Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingNCT05357794Phase 2
• Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2
• Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerRecruitingNCT05288777Phase 2/3
• Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's LymphomaRecruitingNCT05243693Phase 2
• Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05180097Phase 2
• Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingNCT05039073Phase 2
• ATEMPT 2.0: Adjuvant T-DM1 vs THRecruitingNCT04893109Phase 2
• Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaRecruitingNCT04793919Phase 2
• Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingNCT04747912Phase 2
• PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
• Brentuximab Vedotin in Early Stage Hodgkin LymphomaRecruitingNCT04685616Phase 3
• Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionRecruitingNCT04680442Phase 2
• Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasRecruitingNCT04620187Phase 2
• Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaRecruitingNCT04587687Phase 2
• Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingNCT04561206Phase 2
• A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
• Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingNCT04385290Phase 1/2
• BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantRecruitingNCT04378647Phase 2
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
• Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)Not yet recruitingNCT04301375Phase 2
• Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLRecruitingNCT04168502Phase 3
• CLAG-GO for Patients With Persistent, Relapsed or Refractory AMLRecruitingNCT04050280Phase 2
• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingNCT03959085Phase 3
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaRecruitingNCT03737955Phase 2
• Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingNCT03719105Early Phase 1
• Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsRecruitingNCT03587844Phase 2
• Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALLRecruitingNCT03460522Phase 2
• Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First RelapseRecruitingNCT03356054Phase 1/2
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingNCT03150693Phase 3
• Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaRecruitingNCT03104491Phase 1/2
• Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaRecruitingNCT02877303Phase 2
• Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaRecruitingNCT01409161Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT00801489Phase 2
• A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT05687032Phase 4Results posted
• A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)Active, not recruitingNCT05673785Phase 2Results posted
• A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell LymphomaCompletedNCT05442554Phase 4Results posted
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results posted
• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionCompletedNCT04569032Phase 2Results posted
• Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)Active, not recruitingNCT04439110Phase 2Results posted
• Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLActive, not recruitingNCT04404283Phase 3Results posted
• Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113CompletedNCT04070768Phase 1Results posted
• A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaTerminatedNCT03947255Phase 2Results posted
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingNCT03907488Phase 3Results posted
• Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction TherapyCompletedNCT03839446Phase 2Results posted
• Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AMLCompletedNCT03727750Phase 4Results posted
• A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible PatientsCompletedNCT03677596Phase 4Results posted
• ATOP TRIAL: T-DM1 in HER2 Positive Breast CancerActive, not recruitingNCT03587740Phase 2Results posted
• Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid NeoplasmCompletedNCT03531918Phase 1/2Results posted
• Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II StudyActive, not recruitingNCT03517137Phase 2Results posted
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaTerminatedNCT03488225Phase 2Results posted
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaCompletedNCT03409432Phase 2Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03374332Phase 1/2Results posted
• 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerCompletedNCT03364348Phase 1Results posted
• BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaCompletedNCT03264131Phase 2Results posted
• Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaActive, not recruitingNCT03233347Phase 2Results posted
• Brentuximab Vedotin for Systemic SclerosisCompletedNCT03222492Phase 1/2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 2Results posted
• Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic LeukemiaTerminatedNCT03094611Phase 2Results posted
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaActive, not recruitingNCT03057795Phase 2Results posted
• A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted
• A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid TumorsCompletedNCT02999672Phase 2Results posted
• Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell TumorsTerminatedNCT02988843Phase 2Results posted
• A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaActive, not recruitingNCT02979522Phase 1/2Results posted
• Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)CompletedNCT02939014Phase 2Results posted
• Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaActive, not recruitingNCT02758717Phase 2Results posted
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02744612Phase 2Results posted
• Brentuximab Vedotin in Relapsed/Refractory Germ Cell TumorsTerminatedNCT02689219Phase 2Results posted

← Immunotoxins overview